In This Article:
Bausch + Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed out. Bausch + Lomb (BLCO) said it would not pursue a transaction at this time. But it reiterated a view that a full separation from Bausch Health Companies (BHC) is still the goal. Bausch Health Companies owns 88.4% of Bausch + Lomb. So what’s next for the the healthcare icon? Yahoo Finance Executive Editor Brian Sozzi chats with Bausch + Lomb chairman and CEO Brent Saunders. Saunders is known as one of the biggest dealmakers in the pharmaceutical industry of the past 15 years. Saunders returned to Bausch + Lomb as CEO in March 2023. In May 2013, he was also the CEO of Bausch + Lomb, responsible for its $8.7 billion sale to Valeant Pharmaceuticals. He then took over as the CEO of Forest Laboratories. By February 2014, Saunders orchestrated a sale of the company to Actavis for $25 billion. He assumed the CEO position. From there in November 2014, he pulled off a $70 billion acquisition of Allergan and became its CEO. It's there where Saunders' star quickly rose in media circles, overseeing the commercial success of botox and doing battle with feared activist investor Carl Icahn. Saunders then sold Allergan to Abbvie (ABBV) for $63 billion in a deal that closed in May 2020. He says no deal is imminent for Bausch + Lombb.
Related Videos
For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.
Yahoo Finance's Opening Bid is produced by Rachael Lewis-Krisky.